Lloyd Sarah M, Sande Elizabeth J, Ruterbories Kenneth, O'Brien Stephen P, Wang Yue-Ting, Phillips Lucy A, Carr Tracy L, Clements Meghan, Hazelwood Lisa A, Tian Yu, He Yupeng, Ji Qin C
AbbVie Inc., 1 North Waukegan Rd., North Chicago, IL 60064, USA.
AbbVie Bioresearch Center, 100 Research Drive, Worcester, MA 01605, USA.
Int J Mol Sci. 2024 Dec 4;25(23):13026. doi: 10.3390/ijms252313026.
Alterations to post-translational crosslinking modifications in the extracellular matrix (ECM) are known to drive the pathogenesis of fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Thus, the methodology for measuring crosslinking dynamics is valuable for understanding disease progression. The existing crosslinking analysis sample preparation and liquid chromatography tandem mass spectrometry (LC-MS/MS) methods are typically labor-intensive and time-consuming which limits throughput. We, therefore, developed a rapid approach minimizing specialized equipment and hands-on time. The LC-MS/MS sample analysis time was reduced to two minutes per sample. We then improved the analytical integrity of the method by developing a novel surrogate matrix approach for the dihydroxylysinonorleucine (DHLNL) crosslink. By modifying sample preparation, we prepared a tissue-based surrogate matrix with undetectable levels of endogenous DHLNL, providing a strategy for quantifying this crosslink with a more relevant standard matrix. We then applied this rapid methodology to evaluating crosslinking in lung fibrosis. We showed an increase in DHLNL in human IPF lung relative to healthy donors, as well as in a fibrotic mouse model. Finally, we demonstrated that this increase in DHLNL could be mitigated with an anti-fibrotic compound, suggesting that this assay has potential for evaluating pharmaceutical compound efficacy.
已知细胞外基质(ECM)中翻译后交联修饰的改变会推动包括特发性肺纤维化(IPF)在内的纤维化疾病的发病机制。因此,测量交联动力学的方法对于理解疾病进展很有价值。现有的交联分析样品制备和液相色谱串联质谱(LC-MS/MS)方法通常劳动强度大且耗时,这限制了通量。因此,我们开发了一种快速方法,尽量减少专用设备和实际操作时间。LC-MS/MS样品分析时间缩短至每个样品两分钟。然后,我们通过开发一种针对二羟基赖氨酰正亮氨酸(DHLNL)交联的新型替代基质方法,提高了该方法的分析完整性。通过修改样品制备方法,我们制备了一种内源性DHLNL水平不可检测的基于组织的替代基质,为使用更相关的标准基质定量这种交联提供了一种策略。然后,我们将这种快速方法应用于评估肺纤维化中的交联。我们发现,相对于健康供体,人类IPF肺以及纤维化小鼠模型中的DHLNL增加。最后,我们证明这种DHLNL的增加可以用一种抗纤维化化合物减轻,这表明该检测方法具有评估药物化合物疗效的潜力。